About this trial
The goal of this clinical trial is to develop an pharmacist-led preoperative opioid taper intervention for patients undergoing total knee or hip replacement who are on chronic opioids before their surgery. The main questions it aims to answer are:
* Is the intervention feasible and acceptable to patients? * Does the intervention result in a decrease in opioid dose during the preoperative period?
Participants will meet with a clinical pharmacist, who will provide some basic education on pain and opioids, and will propose an opioid taper schedule. The pharmacist will then follow-up with the participant by phone each week until surgery to assess progress and adjust the taper as necessary.
Eligibility criteria
Qualifiers
decided to pursue primary, unilateral total knee or hip arthroplasty with planned surgery date in 4-8 weeks
currently taking between 20 and 90 MME of oral opioids, and that dose has been stable for at least 3 months
have a reliable telephone number for contact
speaks English
Disqualifiers
Buprenorphine
Methadone
Long-acting formulations of opioid pain medications (e.g., extended-release oxycodone and extended-release morphine)
Transdermal formations of opioid pain medications (e.g., fentanyl patches)
Trial design
Treatments tested in this trial
- opioid taper
Treatment groups
Sponsors and collaborators
University of Alabama at Birmingham
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Collaborator